Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited treatment
options. TNBC progression is associated with expansion of cancer stem cells (CSCs). Few …

Background Triple negative breast cancer (TNBC) is clinically aggressive breast cancer with
a poor prognosis. Approximately 20% of TNBC has been found to express programmed …

Bacterial inhabitants of the body have the potential to play a role in various stages of cancer
initiation, progression, and treatment. These bacteria may be distal to the primary tumour …

Simple Summary Based on the latest research progresses, application of immune
checkpoint inhibitors (ICIs) has shown promise in treating breast cancer. Moreover, novel …

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is prone to
metastasis and therapy resistance. Owing to its aggressive nature and limited availability of …

Triple-negative breast cancer (TNBC) comprises a group of aggressive and heterogeneous
breast carcinoma. Chemotherapy is the mainstay for the treatment of triple-negative tumors …

Background The second most frequent cancer in the world and the most common
malignancy in women is breast cancer. Breast cancer is a significant health concern in India …

Neoadjuvant chemotherapy (NAC) may alter the immune landscape of patients with early
breast cancer (BC), potentially setting the scene for more effective implementation of …

Checkpoint immunotherapy has made great strides in the treatment of solid tumors, but
many patients do not respond to immune checkpoint inhibitors. Identification of tumor …

Triple-negative breast cancer (TNBC) has the highest rate of distant metastasis and poorest
overall survival among breast cancer subtypes. In a phase II study, adagloxad simolenin …